Cargando…
The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
Most ovarian cancer cases are diagnosed at an advanced stage (III or IV), in which a primary debulking surgery combined with adjuvant systemic chemotherapy is the standard management. Since targeted therapy is less toxic to human cells than systemic chemotherapy, it has drawn much attention and beco...
Autores principales: | Mao, Chih-Lin, Seow, Kok-Min, Chen, Kuo-Hu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266930/ https://www.ncbi.nlm.nih.gov/pubmed/35805914 http://dx.doi.org/10.3390/ijms23136911 |
Ejemplares similares
-
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
por: Lau, Chien-Hui, et al.
Publicado: (2022) -
Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers
por: Lim, Pei-Qi, et al.
Publicado: (2022) -
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014) -
Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013) -
Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis
por: Song, Li, et al.
Publicado: (2023)